Sino Biopharmaceutical Limited (SBHMY) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Wan Chai, Hong Kong. El CEO actual es S. Y. Tse.
SBHMY tiene fecha de IPO 2017-09-05, 24,379 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $14.2B.
Sino Biopharmaceutical Limited is an investment holding company and research and development pharmaceutical conglomerate headquartered in Hong Kong, operating primarily in the People's Republic of China. The company develops and commercializes a diverse portfolio of pharmaceutical products across multiple therapeutic areas, including oncology, cardio-cerebral vascular, hepatitis, orthopedic, and respiratory medicines, as well as advanced chemical formulations and generic pharmaceuticals. Beyond pharmaceutical manufacturing, the company operates an integrated healthcare ecosystem encompassing hospital operations, pharmaceutical distribution, optometry services, health food production, medical device development, and health information consultancy. Through its three main business segments—Modernised Chinese Medicines and Chemical Medicines, Investment, and Others—Sino Biopharmaceutical serves patients and healthcare providers across China with both traditional and contemporary therapeutic solutions. The company was incorporated in 2000 and maintains a comprehensive value chain from research and development through distribution and patient care services.
